Where does Aurigene Oncology Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aurigene Oncology Limited ranks #17,468 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aurigene Oncology Limited hold?

Aurigene Oncology Limited holds 16 US utility patents granted between 2023 and 2025, spanning 9 technology areas.

What is Aurigene Oncology Limited's Innovation Score?

Aurigene Oncology Limited has an Innovation Score of 50.4 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aurigene Oncology Limited focus on?

Aurigene Oncology Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Aurigene Oncology Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Aurigene Oncology Limited.

What does claim depth mean for Aurigene Oncology Limited's patents?

Aurigene Oncology Limited's patents average 16.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aurigene Oncology Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Aurigene Oncology Limited

USPTO PatentsView assignee record - 16 granted patents across 9 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aurigene ranks #17,468 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 9 technology areas.

#17,468
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.4/100): 16.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R17468 · Foreign Corporation #17,468 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 16 grants
MID-PACK #17,468/49,997
PHOTO-FINISH Astro Technology Group
CPC-NARROW A61P · 9 areas
INNOV-PAR 50.4/100
CLAIMS-RICH 16.7 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Astro Technology Group, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aurigene’s 50.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (19%) Velocity 20.0 pts (40%) Breadth 10.6 pts (21%) Claim depth 10.0 pts (20%)

Qualcomm Incorporated · highest

85
Aurigene Oncology · this assignee

50
3D Lighting… · lowest

7

What this shows Aurigene's Innovation Score is 50.4/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aurigene?

Each dot is one of Aurigene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aurigene’s own 16.7 claims/patent is ABOVE the 14.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aurigene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aurigene's grants concentrate

Aurigene Oncology Limited is a focused PatentsView assignee: 9 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (6 grants) versus a trough of 2 in 2023. By volume, Aurigene sits between Astro Technology Group, LLC and Autotalks Ltd..

Aurigene's three-year grant acceleration

Aurigene Oncology Limited shows 8 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Astro Technology…

16
Atritech

16
Attivo Networks

16
Auria Solutions U…

16
Automated Cashles…

16
Automatic Coating

16
Automotive Coalit…

16
Autotalks

16
Aurigene Oncology ◀

16

What this shows Aurigene holds 16 patents at rank #17,469, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aurigene

By rank, the assignees closest to #17,469 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aurigene's primary technology class.

Aurigene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Aurigene Oncology Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	2	12.5%
2024	6	37.5%
2025partial year	8	50.0%

Which technologies does Aurigene Oncology Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

C07D - Heterocyclic Compounds 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07K - Peptides 2

C07C - Acyclic OR Carbocyclic Compounds 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aurigene Oncology Limited's patent record in context - here's where to go next.

Aurigene Oncology Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,468 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aurigene Oncology Limited against Astro Technology Group, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.